DARPA Awarded Contract for Depression Trial

The $11 million contract funds a clinical trial for a new single-day robotic magnetic stimulation treatment.

Updated on Sept. 30, 2026 in Mental Health

Bold flat-color editorial illustration featuring an abstract navy and cream geometric coil structure, representing advanced medical technology research. — DARPA has awarded an $11.1 million contract to NRx Defense Systems to fund clinical trials of a single-day robotic magnetic stimulation depression treatment. AI Illustration. Upload story photo >

Live Poll

Should federal agencies prioritize funding for rapid, one-day medical treatments for depression?

DARPA has awarded NRx Defense Systems an $11.1 million contract to fund the SPARC-TMS clinical trial. This study evaluates a new treatment protocol that uses robotic magnetic stimulation in combination with the drug NRX-101 for resistant depression.

Why it matters

Current depression therapies are difficult to implement in military environments, prompting a search for a more efficient, single-day treatment. The trial aims to provide a rapid intervention for major depressive disorder that could eventually be deployed in military settings.

The clinical trial (NCT07227103) utilizes a robotic system with 1mm targeting precision to deliver treatment. The study follows data indicating an estimated 8.9 million U.S. adults suffer from treatment-resistant depression.

The players

DARPA

This is the research and development agency of the United States Department of Defense responsible for emerging technologies.

NRx Defense Systems

This entity is a subsidiary of NRx Pharmaceuticals and acts as the primary contractor for the SPARC-TMS clinical trial.

McLean Hospital

This is a psychiatric hospital in Massachusetts that serves as one of the clinical trial sites for the study.

Arizona State University

This institution is participating as a clinical site for the newly launched depression treatment study.

HOPE Therapeutics

This organization is one of the designated sites conducting the robotic magnetic stimulation clinical trial.

The details

The treatment protocol combines d-cycloserine and lurasidone within NRX-101 to improve NMDA receptor function, which was first linked to mental health research by Prof. Daniel Javitt. The entire procedure is designed to be completed in a single day at an outpatient clinic.

Prof. Daniel Javitt reported on the role of NMDA receptors in 1987.
NRx Defense Systems announced the DARPA contract award on September 30, 2026.

The Big Picture

The SPARC-TMS clinical trial serves as the foundational research benchmark for testing robotic magnetic stimulation treatments in military medicine. This project marks a significant step in determining whether advanced, single-day psychiatric protocols can replace traditional long-term therapy.

The study investigates a potential single-day treatment protocol that could eventually offer a faster alternative to traditional therapy sessions. Patients currently living with treatment-resistant depression may have new options for care if the FDA ultimately approves the trial's drug and device combination.

The takeaway

This trial highlights a shift toward using precision robotics and pharmacological combinations to address treatment-resistant mental health conditions. Future clinical results will determine if this intensive, one-day approach effectively manages major depressive disorder for broader populations.